- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
Eli Lilly to Slash Insulin Prices, Cap Monthly Out-of-Pocket Costs at $35
More Americans will soon be paying less for their insulin.
Eli Lilly, one of the three insulin manufacturers, plans to cut its list prices of the drug by 70% and cap out-of-pocket costs at $35 a month.
“While the current health care system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone, and that needs to change,” Eli Lilly CEO David Ricks said in a company statement.
“The aggressive price cuts we’re announcing today should make a real difference for Americans with diabetes. Because these price cuts will take time for the insurance and pharmacy system to implement, we are taking the additional step to immediately cap out-of-pocket costs for patients who use Lilly insulin and are not covered by the recent Medicare Part D cap [on insulin costs],” Ricks added.
The company will cut its list price for Humalog 100 units/mL starting in the fourth quarter of 2023.
It will also cut its list price on non-branded Insulin Lispro Injection 100 units/mL, to $25 a vial. That cut will begin May 1, CBS News reported.
People with insurance will have a cap of $35 on out-of-pocket costs when buying the medication at participating retail pharmacies, the company said.
Those without insurance can also pay just $35 a month by downloading the company’s Insulin Value Program savings card.
That brings the costs in line with enrollees in Medicare, who had prices capped by the Biden administration’s Inflation Reduction Act last year.
Eli Lilly, Novo Nordisk and Sanofi are the three drugmakers that control the insulin market in the United States. About 3 in 10 people with diabetes use Eli Lilly’s insulin.
These drugmakers have been criticized for their high prices, up significantly since they began selling analog insulin products more than 20 years ago, CBS News reported. Some diabetics ration their medication, at great health risk, because of the high price of the medicine.
More information
The American Diabetes Association has more on diabetes.
SOURCES: Eli Lilly, news release, March 1, 2023; CBS News
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.
Related
-
Some Abortion Pill Users Surprised By Pain, Study SaysAbortion pills are safe and effective, but some pain...
- December 20, 2024
-
FDA: Veozah, First Hormone-Free Hot Flash Drug, Issued Black Box WarningThe U.S. Food and Drug Administration (FDA) has issued...
- December 18, 2024
-
Non-heterosexual Women Report Better Sexual Functioning During MidlifeTUESDAY, Dec. 17, 2024 A woman’s sex drive often...
- December 18, 2024
-
Task Force Supports Women Over 30 Collecting Samples for Cervical Cancer ScreeningIn guidelines that may encourage more women to get...
- December 10, 2024
